01Jul
Novartis and Alcon FCPA Enforcement Action: Lessons Learned (Part III of III)
At the outset, Novartis is “lucky” – the settlement is relatively positive, despite its 2016 SEC enforcement action in China. Given Novartis weak culture of compliance (if anything, a better description may be a culture of non-compliance) and its status as a recidivist, Novartis could have been slammed with a stiffer enforcement action, including assignment of an independent corporate compliance monitor and a higher penalty. ...
By:
Michael Volkov
Related
World Law Group member firms recently collaborated on a Global Venture Capital Guide that covers mor...
Read More >
Office workers who perform secretarial, receptionist and other administrative tasks are often incorr...
Read More >
The U.S. Department of Homeland Security (DHS) has instituted a new compliance activity which could ...
Read More >
Big-Tech/Antitrust Update: the FTC has demanded information from Amazon.com Inc., Apple Inc., Facebo...
Read More >
A common feature of some contracts, including construction and design contracts, is a limitation of ...
Read More >
Seyfarth Synopsis: The U.S. Department of Labor’s Wage & Hour Division issued a proposed rule on th...
Read More >